A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer, Cancer, vol.19, issue.11, pp.2438-2446, 2009. ,
DOI : 10.7326/0003-4819-144-7-200604040-00009
Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab, Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.1003
Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma, Journal of Clinical Oncology, vol.22, issue.5, pp.909-918, 2004. ,
DOI : 10.1200/JCO.2004.08.185
A phase I trial of RAD001 in combination with cetuximab in patients with advanced solid tumors, J Clin Oncol, vol.25, p.14075, 2007. ,
A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer, Cancer, vol.19, issue.11, pp.2438-2484, 2009. ,
DOI : 10.7326/0003-4819-144-7-200604040-00009
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor???Positive Breast Cancer, Journal of Clinical Oncology, vol.27, issue.16, pp.2630-2637, 2009. ,
DOI : 10.1200/JCO.2008.18.8391
results of a phase I study of bevacizumab, everolimus and erlotinib in patients with advanced solid tumors, J Clin Oncol, vol.25, 2007. ,
La rapamycine : identification d'une nouvelle voie de signalisation des facteurs de croissance, r??glant le d??but de la traduction, m??decine/sciences, vol.14, issue.5, pp.600-602, 1998. ,
DOI : 10.4267/10608/1099
Nouveautés thérapeutiques dans le cancer du rein : espoirs et questions. Revue médicale suisse, pp.1288-1296, 2007. ,
A phase II study of oral mammalian target of rapamycin(mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma, J Clin Oncol, vol.26, issue.5502, p.161, 2008. ,
Bevacizumab plus everolimus in refractory metastatic colorectal cancer, J Clin Oncol, vol.27, 2009. ,
A phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma (mRCC), J Clin Oncol, vol.27, p.16056, 2009. ,
Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer, Journal of Clinical Oncology, vol.23, issue.23, pp.5314-5336, 2005. ,
DOI : 10.1200/JCO.2005.66.130
A phase II study of mammalian target of rapamycin (mTOR) inhibitor RAD001 plus imatinib mesylate in patients with previously treated advanced renal carcinoma, J Clin Oncol, vol.25, 2007. ,
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme, Investigational New Drugs, vol.19, issue.4, pp.357-61, 2005. ,
DOI : 10.1016/S0002-9440(10)61702-6
phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas, J Clin Oncol, vol.27, 2004. ,
Survival results with AP23573, a novel inhibitor, in patients with advanced soft tissue or bone sarcomas : a phase II trial, J Clin Oncol, vol.24, p.10076, 2006. ,
A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer, J Clin Oncol, vol.25, p.5516, 2007. ,
Les inhibiteurs de la voie PI3 kinase-AKT-mTOR, Bull Cancer, vol.93, pp.19-26, 2006. ,
Voies de signalisation de la PI3K et de mTOR : perspectives de l'utilisation de la rapamycine et de ses dérivés en thérapie antitumorale ciblée, Bull Cancer, vol.hors série, pp.31-40, 2006. ,
Actualités sur la voie mTOR et ses inhibiteurs, Bull Cancer, vol.96, pp.87-94, 2009. ,
A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinibresistant gastrointestinal stromal tumors (GIST), J Clin Oncol, vol.26, p.162, 2008. ,
Therapeutic potential of target of rapamycin inhibitors, Expert Opinion on Therapeutic Targets, vol.11, issue.17, pp.551-564, 2004. ,
DOI : 10.1016/S1097-2765(03)00180-1
A randomized phase II study of two different schedules of RAD001 in patients with recurrent/ metastatic breast cancer, J Clin Oncol, vol.25, 2007. ,
Current development of mTOR inhibitors as anticancer agents, Nature Reviews Drug Discovery, vol.10, issue.Abs. LBA 4, pp.671-688, 2006. ,
DOI : 10.1158/1078-0432.CCR-04-0035
Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors, Journal of Clinical Oncology, vol.25, issue.30, pp.4806-4812, 2007. ,
DOI : 10.1200/JCO.2007.11.4017
Phase I study of everolimus + low dose weekly cisplatin for patients with advanced solid tumors: preliminary results, J Clin Oncol, vol.27, 2009. ,
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study, Journal of Clinical Oncology, vol.23, issue.23, pp.5294-304, 2005. ,
DOI : 10.1200/JCO.2005.23.622
A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC), Journal of Clinical Oncology, vol.26, issue.15_suppl, p.14603, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.14603
Insights into the PI3-K-PKB-mTOR signalling pathway from small molecules, Journal of Chemical Biology, vol.3, issue.1-4, pp.49-62, 2008. ,
DOI : 10.4049/jimmunol.170.5.2647
A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma, J Clin Oncol, vol.27, 2009. ,
Upstream and downstream of mTOR, Genes & Development, vol.18, issue.16, pp.1926-1945, 2004. ,
DOI : 10.1101/gad.1212704
Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator???s choice therapy, Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.8513
Phase I evaluation of lapatinib and everolimus in patients with advanced malignancies: Southwest Oncology Group trial S0528, J Clin Oncol, vol.27, 2009. ,
Bevacizumab plus everolimus and panitumumab in refractory advanced solid tumors, J Clin Oncol, vol.27, pp.3551-163, 2009. ,
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.22, pp.2271-2281, 2007. ,
DOI : 10.1056/NEJMoa066838
Signaling by Target of Rapamycin Proteins in Cell Growth Control, Microbiology and Molecular Biology Reviews, vol.69, issue.1, pp.79-100, 2005. ,
DOI : 10.1128/MMBR.69.1.79-100.2005
A phase II trial of RAD001 in patients with metastatic renal cell carcinoma, J Clin Oncol, vol.25, 2007. ,
A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy, Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.5113
Phase II trial of the oral of mTOR inhibitor everolimus for patients with relapsed or refractory lymphoma, J Clin Oncol, vol.25, 2007. ,
Updated data from a phase III randomised trial of everolimus versus PBO in metastatic renal cell carcinoma, Genitourinary Cancers Symposium, 2009. ,
Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: a phase I study, J Clin Oncol, vol.27, 2009. ,
Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma, J Clin Oncol, vol.27, 2009. ,
Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma, J Clin Oncol, vol.27, p.9026, 2009. ,
The Applicability of mTOR Inhibition in Solid Tumors, Current Cancer Drug Targets, vol.9, issue.3, pp.439-450, 2009. ,
DOI : 10.2174/156800909788166556
Phase II study of RAD001 in previously treated small cell lung cancer, J Clin Oncol, vol.27, 2009. ,
Combined inhibition of mTOR and EGFR with everolimus and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: a phase II trial, J Clin Oncol, vol.25, p.7575, 2007. ,
Everolimus (RAD001) et tumeurs solides : le point en, Bull Cancer, vol.95, pp.1205-1211, 2008. ,
mTOR, translation initiation and cancer, Oncogene, vol.25, issue.48, pp.6416-6422, 2006. ,
DOI : 10.1038/sj.onc.1209495
URL : http://www.nature.com/onc/journal/v25/n48/pdf/1209888a.pdf
CCI-779 in metastatic melanoma, Cancer, vol.4, issue.5, pp.1045-1048, 2005. ,
DOI : 10.1200/JCO.2004.04.072
A phase I trial of liposomal doxorubicin, bevacizumab and temsirolimus in advanced malignancy, J Clin Oncol, vol.27, 2009. ,
Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.25, issue.25, pp.3958-3964, 2007. ,
DOI : 10.1200/JCO.2006.10.5916
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, The Lancet, vol.372, issue.9637, pp.449-456, 2008. ,
DOI : 10.1016/S0140-6736(08)61039-9
Phase I trial of escalating doses of weekly everolimus in combination with docetaxel for the treatment of metastatic breast cancer, J Clin Oncol, vol.27, p.1066, 2009. ,
Multicenter phase II study of RAD001 for previously treated metastatic gastric cancer (MGC): Preliminary results, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.4541, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.4541
Phase I study combining an IGFR inhibitor (IMC-A12) and an mTOR inhibitor (temsirolimus) in patients with solid tumors or lymphoma, J Clin Oncol, vol.27, 2009. ,
A multicenter phase 2 consortium study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas, J Clin Oncol, vol.24, 2006. ,
Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC), Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.19017
Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer, J Clin Oncol, vol.24, 2006. ,
A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b, Journal of Clinical Oncology, vol.26, issue.15_suppl, pp.5516-165, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.5516
Phase I study of temsirolimus, carboplatin and paclitaxel in patients with advanced solid tumors : NCIC CTG IND 179, 2009. ,
Inhibiteurs de mTOR : Des antiprolif??ratifs pl??iotropiques, m??decine/sciences, vol.22, issue.11, pp.947-952, 2006. ,
DOI : 10.1051/medsci/20062211947
A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500), Journal of Thoracic Oncology, vol.2, issue.11, pp.1036-1077, 2007. ,
DOI : 10.1097/JTO.0b013e318155a439
A phase II study of RAD001 monotherapy in patients with advanced non-small cell lung cancer failing prior platinium-based chemotherapy or prior chemotherapy and EGFR inhibitors, J Clin Oncol, vol.25, p.7589, 2007. ,
A phase1/2study investigating the combination of RAD001 (everolimus) and erlotinib as 2nd and 3rd line therapy in patients with advanced non-small cell lung cancer previously treated with chemotherapy: phase 1 results, J Clin Oncol, vol.26, 2008. ,
Evaluation of safety, tolerability and activity: a registry for temsirolimus-treated patients with advanced or metastatic renal cell carcinoma in the usual health care setting, J Clin Oncol, vol.27, 2009. ,
A phase I study of temsirolimus and bryostatin in patients with metastatic renal cell carcinoma, J Clin Oncol, vol.27, 2009. ,
N0377 : Results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma, J Clin Oncol, vol.25, 2007. ,
De la chimiothérapie classique à la chimiothérapie ciblée : les mécanismes de l'oncogenèse aux niveaux cellulaire et moléculaire, Bull Cancer, vol.hors série, pp.5-16, 2006. ,
Qu'est ce qu'une thérapeutique ciblée ? Le point de vue du biologiste, Bull Cancer, vol.94, pp.101-110, 2007. ,
Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.5109, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.5109
Phase II study of everolimus with imatinib in patients with previously-treated renal cell carcinoma (RCC), J Clin Oncol, vol.27, 2009. ,
NCCTG phase I trialof temsirolimus and temozolomide in combination with radiation therapy in newly diagnosed glioblastoma multiforme patients, J Clin Oncol, vol.27, 2009. ,
Temsirolimus in metastatic renal cell carcinoma: safety and efficacy in patients previously treated with VEGF-targeted therapy, Genitourinary Cancers Symposium, 2009. ,
Phase I study of RAD001, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer, J Clin Oncol, vol.27, 2009. ,
A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC), Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.5502
Qu'est ce qu'une thérapie ciblée ? Le point de vue du clinicien, Bull Canc, vol.94, pp.111-114, 2007. ,
mTOR-targeted therapy of cancer with rapamycin derivatives, Annals of Oncology, vol.16, issue.4, pp.525-537, 2005. ,
DOI : 10.1093/annonc/mdi113
phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma, J Clin Oncol, vol.27, 2006. ,
Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC), Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.5010
Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.4614, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.4614
Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer: main results, Gastointestinal Cancers Symposium, 2009. ,
Phase II study of RAD001 and depot octreotide in advanced low grade neuroendocrine carcinoma, J Clin Oncol, vol.25, p.4503, 2007. ,
Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study, Journal of Clinical Oncology, vol.26, issue.26, pp.4311-4318, 2008. ,
DOI : 10.1200/JCO.2008.16.7858
A phase II trial of daily oral RAD001 in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy, 2009. ,
Le concept de cible en cancérologie, John Libbey Eurotext et AMGEN, 2008. ,